871026-10-7

Upstream product

• 39252-69-2 2-iodoethyl benzoate 
• 84905-80-6 4-Chloro-5H-pyrrolo[3,2-d]pyrimidine 
• 939-54-8 2-bromoethyl benzoate 

Downstream Products

• 1033806-48-2 N-(tert-butyl)-5-(2-chloro-4-{[5-(2-hydroxyethyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl]amino}phenoxy)pyridine-2-carboxamide 
• 1033809-06-1 C₂₉H₂₂ClN₅O₄ 
• 1033808-77-3 2-[4-({3-chloro-4-[(1-methyl-2-oxo-2,3-dihydro-1H-indol-4-yl)oxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl benzoate 
• 1033809-02-7 C₃₁H₂₉ClN₆O₄ 
• 1033809-16-3 C₃₀H₂₄ClN₅O₄ 
• 1033809-29-8 C₃₁H₂₆ClN₅O₄ 
• 1033809-35-6 C₃₂H₂₈ClN₅O₄ 
• 1033809-49-2 C₃₂H₃₁ClN₆O₄ 
• 1033809-57-2 C₃₀H₂₄ClN₅O₄ 
• 1033809-64-1 C₃₁H₂₄ClF₃N₄O₄ 
• 1033809-82-3 C₃₁H₂₆ClN₅O₃ 
• 1033810-02-4 C₃₀H₂₂ClN₅O₃ 
• 1033810-05-7 C₃₀H₂₁ClFN₅O₃ 
• 1033810-08-0 C₃₁H₂₁ClF₃N₅O₃ 

Relevant academic research and scientific papers

Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold

Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer. To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivatives capable of fitting into the receptors' ATP binding site. Among the prepared compounds, 34e showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity. The X-ray cocrystal structures of 34e with both HER2 and EGFR demonstrated that 34e interacts with the expected residues in their respective ATP pockets. Furthermore, reflecting its good oral bioavailability, 34e exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models. On the basis of these findings, we report 34e (TAK-285) as a promising candidate for clinical development as a novel HER2/EGFR dual kinase inhibitor.

N-Phenyl-N′-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases

We have recently reported the discovery of pyrrolo[3,2-d]pyrimidine derivatives 1a and 1b as potent triple inhibitors of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and Tie-2 kinases. To identify compounds having strong inhibitory activity against fibroblast growth factor receptor (FGFR) kinase, further modification was conducted using the co-crystal structure analysis of VEGFR2 and 1b. Among the compounds synthesized, urea derivative 11l having a piperazine moiety on the terminal benzene ring showed strong inhibitory activity against FGFR1 kinase as well as VEGFR2 kinase. A binding model of 11l complexed with VEGFR2 suggested that the piperazine moiety forms additional interactions with Ile1025 and His1026.

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a compound represented by the formula: wherein W is C(R 1 ) or N, each A is an optionally substituted aryl group or a heteroaryl group, X 1 is -NR 3 -Y 1 -, -O-, -S-, -SO-, -SO 2 or -CHR 3 - wherein R 3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R 3 is optionally bonded to A to form an optionally substituted ring structure, R 1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R 2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R 1 and R 2 , or R 2 and R 3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.